“The president’s case is a case of one, and that’s what we call a case report, and it is evidence of what’s happening, but it’s kind of the weakest evidence that you can get,” Schleifer said in an interview on CBS’ “Face the Nation.”
“The real evidence has to come about how good a drug is and what it will do on average has to come from these large clinical trials, these randomized clinical trials, which are the gold standard. And those are ongoing,” Schleifer said. “We’ve got some preliminary evidence that we’ve talked with the FDA, and we’re going for an emergency use authorization, because we think it’s appropriate at this time.”
Trump, who was hospitalized at Walter Reed National Military Medical Center after being diagnosed with coronavirus, was treated with the experimental antibody drug and touted it as a “cure.” In an interview Sunday with Fox News host Maria Bartiromo, Trump said he’s beaten Covid-19 and claimed immunity from the virus.